The biggest advance in RA over the last two decades wasn't a new drug — it was a strategy. Instead of loosely managing symptoms, modern care sets a hard target, measures relentlessly, and escalates until you hit it. It's a large part of why RA today is so different from a generation ago.
RA is tracked with composite disease-activity scores — most commonly DAS28, which combines tender and swollen joint counts, your own global rating, and an inflammation marker into a single number. The bands: remission below 2.6, low activity up to 3.2, moderate up to 5.1, high above that (CDAI and SDAI are similar alternatives). These turn 'how are you feeling' into something objective and trackable. Evidence ●●●●○
The treat-to-target approach sets an explicit goal (remission, or at least low disease activity), measures it every 1–3 months while disease is active, and escalates treatment until the target is reached and held. The landmark TICORA trial showed this tight, systematic control produces far better outcomes — more remission, less joint damage — than routine care, at no extra cost. How you deliver treatment matters as much as which drug you use. Evidence ●●●●●
The DMARDs that control RA need routine safety bloods — methotrexate, for instance, needs blood-count, liver, and kidney checks every couple of weeks at first, then roughly every three months — to catch the rare liver, blood, or kidney effects early. It's the trade that makes powerful long-term therapy safe, and it's why 'set and forget' isn't an option. Evidence ●●●●○
Don't accept 'moderate' as good enough
The highest-leverage thing you can do as a patient is get to remission or low disease activity fast and hold it. Ask your rheumatologist what your DAS28 (or CDAI) is and what the target is — tight control early is what protects your joints for life.
The RA Guide